IR BioSciences Holdings Inc. (IRBS.OB) Subsidiary Announces Positive Immune Response of Lead Compound Homspera
ImmuneRegen BioSciences Inc., a wholly owned subsidiary of IR BioSciences Holdings Inc., today updated recent results of a study for its lead compound Homspera®. In combination with a DNA vaccine using Scancell’s patented ImmunoBody® technology, Homspera significantly improved the immune response of the vaccine in an animal model. ImmuneRegen said it's currently conducting follow-up studies to optimize Homspera’s efficacy in enhancing the next generation of Scancell's cancer vaccines. Scancell recently started a phase I clinical trial for SCIB1, its novel product in development for the treatment of melanoma centered on its ImmunoBody technology. Scancell's Immunobody technology is unique in that…